ea0070ep124 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020
Lzkhakov Elena
, Shacham Yakov
, Yaron Mariana
, Serebro Merav
, Tordjman Karen
, Greenman Yona
, Stern Naftali
, Ziv Tomer
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors decrease the degradation of low–density lipoprotein (LDL) receptors, thereby increasing the removal of LDL particles from the blood and significantly reducing LDL cholesterol levels by an average of 65%. Blom et al. showed changes in vitamin E, adrenocorticotropic hormone (ACTH), cortisol, total testosterone, and estradiol in EVOLOCUMAB (PCSK9 inhibitor)–treated patients 1. Ther...